argenx, an international biotechnology company, has made significant progress in multiple areas. The market momentum reflects on the company’s true valuation, bolstered by its robust financial performance.
argenx announced the authorization for the sale of
VYVGART SC prefilled Syringe for self-injection in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) by Health Canada. Reportedly, the
argenx NV ADR has experienced a major surge, hitting an all-time high of 855.68 USD. Its notable progress on
Vyvgart trials aligns with company’s commitment to ensure that no MG patient is left behind. The company’s stock volume spiked and saw a rise due to increased sales of its Vyvgart medication. Amid strong Vyvgart sales, renowned company Piper Sandler raised
argenx’s stock price target to $930. Key data and the breadth of immunology innovation were highlighted at
argenx's 2025 AANEM Annual Meeting and MGFA Scientific Session. Furthermore,
argenx expanded its global partnership with FUJIFILM Biotechnologies. The company's Q3 2025 financial report revealed record sales and significant pipeline advancements. Deutsche Bank upgraded
argenx from hold to buy.
argenx News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Fri, 07 Nov 2025 20:19:16 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -2
